23andMe
23andMe is a consumer genetics and research company that provides direct-to-consumer genetic testing services for ancestry, health predispositions, and traits, and leverages its genetic database for drug discovery and research partnerships. The company combines consumer-facing products with a biopharma business that develops therapeutics based on aggregated genetic insights.
Layoff history
EMPLOYEES AFFECTED PER QUARTER · HOVER FOR DETAILS
Layoff timeline
2 EVENTS23andMe announced a major restructuring that will cut 40% of its workforce — described as "over 200 employees" — and eliminate its therapy programs including cancer-treatment research. The company plans to wind down clinical trials, explore licensing and asset sales of therapeutic programs, and refocus on its core direct-to-consumer genetic testing and data sales to pharma. CEO Anne Wojcicki framed the reductions as necessary to stabilize the business amid declining demand for DNA kits, a prior large data breach, failed SPAC-era momentum, board resignations, and doubts about the company’s ability to continue. The restructuring is expected to save about $35 million annually as 23andMe tightens its focus and reduces its research footprint.
Stories from here
No one has shared a story from 23andMe yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →Get alerts for 23andMe
We'll email you the moment a new layoff is reported here.